NISTmAb, the world's first standardized monoclonal antibody has become a valuable tool for biomanufacturers developing new biologic therapies for cancers, autoimmune disorders and infectious diseases. Although the molecule has been precisely characterized, the current proprietary method for its production has not. In a new article, researchers describe how they have taken the first step to solve this dilemma: engineering three mouse cell lines to produce nonproprietary versions of NISTmAb that closely resemble the characteristics of the original reference material.
from Top Health News -- ScienceDaily https://ift.tt/2mYipz7
Subscribe to:
Post Comments (Atom)
-
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one ...
-
Three treaties between the US and Hong Kong were suspended, the latest move to pressure China. from Yahoo News - Latest News & Headl...
-
At least 22 people were killed and 171 others injured on Sunday when one of Taiwan’s newer, faster trains derailed on a curve along a popula...
No comments:
Post a Comment